Although the development of new generation Chimeric Antigen Receptor (CAR)-T cells with co-stimulatory domains has improved T cell persistence, survival, and cytokine secretion; tumors can inhibit the anti-tumor potency of these cells through the TGF-β pathway. The gene discussed is TGFB1; the disease is neoplasm.